利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

15 records (took 0.016 seconds)

    Human papilloma virus genes and their use in gene therapy
    3.
    发明授权
    Human papilloma virus genes and their use in gene therapy 失效
    人类乳头状瘤病毒基因及其在基因治疗中的应用

    公开(公告)号：US5576206A

    公开(公告)日：1996-11-19

    申请号：US246704

    申请日：1994-05-20

    Applicant: Richard Schlegel

    Inventor： Richard Schlegel

    IPC: A61K48/00 ,  C07K14/025 ,  C12N5/22 ,  C12N15/85

    CPC classification number: C07K14/005 ,  A61K48/00 ,  C12N2710/20022

    Abstract: A process of immortalizing cells with isolated HPV-16, 18, 31, 33 or 35 E6 and E7 genes or the E7 gene alone to produce non-tumorigenic immortalized cell lines which retain the differentiated phenotypic characteristics of the parent cells.

    Abstract translation: 用分离的HPV-16,18,33,33或35E6和E7基因或单独的E7基因使细胞永生化以产生保留母细胞的分化表型特征的非致瘤性永生化细胞系的过程。

    Papillomavirus vaccines
    6.
    发明授权
    Papillomavirus vaccines 失效
    乳头瘤病毒疫苗

    公开(公告)号：US08012679B1

    公开(公告)日：2011-09-06

    申请号：US08764926

    申请日：1996-12-16

    Applicant: C. Richard Schlegel ,  A. Bennett Jenson

    Inventor： C. Richard Schlegel ,  A. Bennett Jenson

    IPC: C12Q1/70

    CPC classification number: C07K14/005 ,  A61K39/00 ,  C12N2710/20022 ,  C12N2710/20034

    Abstract: Seven polyclonal and monoclonal antibodies were characterized for their ability to react specifically with either conformational or non-conformational epitopes of the HPV-1 virion. Using these antibodies, it was shown that the HPV-1 L1 protein (when expressed by an SV40 vector in cos cells) displayed conformational epitopes characteristic of intact viral particles. In addition, the L1 capsid protein was translocated normally into cell nuclei, was of appropriate size (57kD), and could be isolated in native form by immunoprecipitation techniques. Most importantly, the screening of expressed papillomavirus capsid proteins for reactivity with conformation-dependent antibodies represents a new, general methodology for ensuring that such proteins will be suitable for use in vaccine development or in the serologic detection/typing of human papillomavirus infections.

    Abstract translation: 表征了七种多克隆和单克隆抗体与HPV-1病毒体的构象或非构象表位特异性反应的能力。 使用这些抗体，显示HPV-1 L1蛋白质（当在COS细胞中由SV40载体表达时）显示完整病毒颗粒特征的构象表位。 此外，L1衣壳蛋白通常转位到细胞核中，具有适当的大小（57kD），并且可以通过免疫沉淀技术以天然形式分离。 最重要的是，筛选表达的乳头状瘤病毒衣壳蛋白与构象依赖性抗体的反应性代表了一种新的通用方法，用于确保这些蛋白质适用于疫苗开发或人乳头状瘤病毒感染的血清学检测/分型。

    Diagnosis and treatment of cervical cancer
    7.
    发明申请
    Diagnosis and treatment of cervical cancer 审中-公开
    诊断和治疗宫颈癌

    公开(公告)号：US20070065810A1

    公开(公告)日：2007-03-22

    申请号：US10565021

    申请日：2004-07-16

    Applicant: Richard Schlegel

    Inventor： Richard Schlegel

    IPC: C12Q1/70 ,  C12Q1/68

    CPC classification number: G01N33/57411 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/178 ,  G01N2333/4706 ,  G01N2333/65 ,  G01N2333/79 ,  G01N2333/91245

    Abstract: In certain aspects, the invention relates to methods of diagnosing cervical cancer by using a combination of certain biomarkers such as hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length. In other aspects, the invention relates to methods of detecting immortalization of cervical cells by using a combination of certain biomarkers. In yet other aspects, the invention relates to methods of classifying the grade of a cervical lesion for diagnostic and prognostic purposes in a female. In further aspects, the invention relates to methods of treating cervical cancer by administering a therapeutic agent that targets one or more of these biomarkers.

    Abstract translation: 在某些方面，本发明涉及通过使用某些生物标志物如hTERT，IGFBP-3，转铁蛋白受体，β-连环蛋白，Myc-HPV E6相互作用，HPV E7和端粒长度的组合来诊断子宫颈癌的方法。 在其他方面，本发明涉及通过使用某些生物标志物的组合来检测宫颈细胞的永生化的方法。 在另一方面，本发明涉及在女性中对用于诊断和预后目的的子宫颈病变等级进行分类的方法。 在另外的方面，本发明涉及通过施用靶向这些生物标志物中的一种或多种的治疗剂来治疗子宫颈癌的方法。

Patent Agency Ranking